Skip to content

SMS alerts to reduce toxicity and improve treatment compliance in cancer chemotherapy: A clinical trial

Mobile Short Message Service (SMS) alerts for reducing the toxicity and improving protocol compliance during cancer chemotherapy: A randomized controlled trial - SMS study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/02/005491
Enrollment
400
Registered
2015-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C169- Malignant neoplasm of stomach, unspecified Health Condition 2: null- Stomach and Colorectal cancer patients on chemotherapy

Interventions

Intervention1: Text message (SMS): Patients in the intervention arm will receive, in addition to standard written instructions, periodic SMS after 4th, 7th and 14th day of starting first cycle of chem

Sponsors

Tata Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Provide informed consent and sign the patient information sheet - Own a mobile phone with text message (SMS) facility. - Diagnosed with stomach cancer (all histological types) and are planned for peri-operative chemotherapy (before surgery) with EOX protocol i.e. combination of Epirubicin, Oxaliplatin and Capecitabine given every 3 weeks. - Diagnosed with colorectal cancer (post-surgery and/or radiotherapy, including metastatic disease) and planned to start on adjuvant or palliative chemotherapy with CapOx protocol i.e. combination of Capecitabine and Oxaliplatin given every 3 weeks. - Residing within 50km radius of TMC. - Patient or any of his/her immediate family member(s) who are able to read and comprehend text message in English

Exclusion criteria

Exclusion criteria: - Not a citizen of India e.g. patients from neighbouring countries like Bangladesh, Nepal, Bhutan. - Non-resident Indians i.e. Indians residing outside India but visiting India for cancer treatment

Design outcomes

Primary

MeasureTime frame
- Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) - Number of delayed chemotherapy cycles due to toxicity - Number of dose reductions due to severe toxicity Timepoint: NA

Secondary

MeasureTime frame
- Overall cost of treatment and out of pocket expenditureTimepoint: NA

Countries

India

Contacts

Public ContactTanuj Chawla

Tata Medical Center

tanujucms@yahoo.com918420711222

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 21, 2026